Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 2 de 2
Filtrar
Mais filtros










Base de dados
Intervalo de ano de publicação
1.
JAMA ; 320(24): 2564-2579, 2018 12 25.
Artigo em Inglês | MEDLINE | ID: mdl-30575881

RESUMO

Importance: Even though osteoarthritis is a chronic and progressive disease, pharmacological agents are mainly studied over short-term periods, resulting in unclear recommendations for long-term disease management. Objective: To search, review, and analyze long-term (≥12 months) outcomes (symptoms, joint structure) from randomized clinical trials (RCTs) of medications for knee osteoarthritis. Data Sources and Study Selection: The databases of MEDLINE, Scopus, EMBASE, Web of Science, and the Cochrane Central Register of Controlled Trials were searched until June 30, 2018 (MEDLINE alerts through August 31, 2018) for RCTs of patients with knee osteoarthritis that had treatment and follow-up lasting 1 year or longer. Data Extraction and Synthesis: Data at baseline and at the longest available treatment and follow-up of 12 months' duration or longer (or the change from baseline) were extracted. A Bayesian random-effects network meta-analysis was performed. Main Outcomes and Measures: The primary outcome was the mean change from baseline in knee pain. Secondary outcomes were physical function and joint structure (the latter was measured radiologically as joint space narrowing). Standardized mean differences (SMDs) and mean differences with 95% credibility intervals (95% CrIs) were calculated. Findings were interpreted as associations when the 95% CrIs excluded the null value. Results: Forty-seven RCTs (22 037 patients; mean age range, mostly 55-70 years; and a higher mean proportion of women than men, around 70%) included the following medication categories: analgesics; antioxidants; bone-acting agents such as bisphosphonates and strontium ranelate; nonsteroidal anti-inflammatory drugs; intra-articular injection medications such as hyaluronic acid and corticosteroids; symptomatic slow-acting drugs in osteoarthritis such as glucosamine and chondroitin sulfate; and putative disease-modifying agents such as cindunistat and sprifermin. Thirty-one interventions were studied for pain, 13 for physical function, and 16 for joint structure. Trial duration ranged from 1 to 4 years. Associations with decreases in pain were found for the nonsteroidal anti-inflammatory drug celecoxib (SMD, -0.18 [95% CrI, -0.35 to -0.01]) and the symptomatic slow-acting drug in osteoarthritis glucosamine sulfate (SMD, -0.29 [95% CrI, -0.49 to -0.09]), but there was large uncertainty for all estimates vs placebo. The association with pain improvement remained significant only for glucosamine sulfate when data were analyzed using the mean difference on a scale from 0 to 100 and when trials at high risk of bias were excluded. Associations with improvement in joint space narrowing were found for glucosamine sulfate (SMD, -0.42 [95% CrI, -0.65 to -0.19]), chondroitin sulfate (SMD, -0.20 [95% CrI, -0.31 to -0.07]), and strontium ranelate (SMD, -0.20 [95% CrI, -0.36 to -0.05]). Conclusions and Relevance: In this systematic review and network meta-analysis of studies of patients with knee osteoarthritis and at least 12 months of follow-up, there was uncertainty around the estimates of effect size for change in pain for all comparisons with placebo. Larger RCTs are needed to resolve the uncertainty around efficacy of medications for knee osteoarthritis.


Assuntos
Corticosteroides/uso terapêutico , Analgésicos/uso terapêutico , Anti-Inflamatórios não Esteroides/uso terapêutico , Celecoxib/uso terapêutico , Osteoartrite do Joelho/tratamento farmacológico , Manejo da Dor/métodos , Idoso , Conservadores da Densidade Óssea/uso terapêutico , Feminino , Seguimentos , Glucosamina/uso terapêutico , Humanos , Injeções Intra-Articulares , Masculino , Pessoa de Meia-Idade
2.
Med Ref Serv Q ; 29(2): 132-45, 2010 Apr.
Artigo em Inglês | MEDLINE | ID: mdl-20432137

RESUMO

The new Web generations are influencing the minds and changing the habits of software developers and end users. Users, librarians, and information services professionals can interact more efficiently, creating additional information and content and generating knowledge. This new scenario is also changing the behavior of information providers and users in health sciences libraries. This article reviews the new Web environments and tools that give librarians opportunities to tailor their services better, and gives some examples of the advantages and disadvantages for them and their users. Librarians need to adapt to the new mindset of users, linking new technologies, information, and people.


Assuntos
Difusão de Inovações , Internet , Serviços de Biblioteca/organização & administração
SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA
...